SELECT PUBLICATIONS

Albain K et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). San Antonio Breast Cancer Symposium 2004;Abstract 37.

Chlebowski RT et al. Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women’s Intervention Nutrition Study (WINS). Proc ASCO 2005;Abstract 10.

Duffy SR, Distler W, on Behalf of the ATAC Trialists' Group. Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: Results from the ATAC trial. San Antonio Breast Cancer Symposium 2005;Abstract 2056.

Fallowfield L et al. Patients' preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Ann Oncol 2006;17(2):205-10. Abstract

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract

Jakesz R et al; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract

Jonat W et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone responsive early breast cancer: A meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 18.

HERA Study Team. Trastuzumab (H: Herceptin^®) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: The HERA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 11. 

Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104(2):236-9. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial conducted by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol2005;23(4):792-9. Abstract

Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005;Abstract 556.

Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium 2005;Abstract 1045.

Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials.Cancer 2003;98(2):229-38. Abstract

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005. No abstract available

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Storniolo AM et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. San Antonio Breast Cancer Symposium 2005;Abstract 1073.

Thürlimann B et al. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind Phase III study. Breast 2005;14(Suppl 1):3;S4.